Guardian Pharmacy Q2 revenue beats estimates; 2026 outlook lifted
GRDN•What drove the results
- IRA price reductions — The company said IRA-related pricing reductions limited reported revenue growth in the second quarter.
- Operating efficiency — Guardian attributed expanded profitability to benefits of scale, purchasing leverage and improved operating efficiency.
- Residents served — Residents served grew 8% year over year, contributing to business growth.
Analyst coverage and valuation
The current average analyst rating on the shares is "strong buy", with 6 recommendations rated "strong buy" or "buy", and no "hold" or "sell"/"strong sell" ratings.
The average consensus recommendation for the drug retailers peer group is "buy."
Wall Street's median 12-month price target for Guardian Pharmacy Services, Inc. is $47.00, about 16% above its August 5 closing price of $40.50.
The stock recently traded at the next 12-month earnings versus a three months ago.
